Published Date: 16-Jun-2020
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Global Osteoporosis Drugs Market, published by KBV research, The Global Osteoporosis Drugs Market size is expected to reach $10.9 billion by 2026, rising at a market growth of 4.4% CAGR during the forecast period.
Due to the abundant availability of medicinal products, which are available as oral medicines, the oral market has acquired the major share of the osteoporosis market through its administration. Instead, due to factors such as an increase in drug need to demonstrate better bioavailability rapid modes of action, the injectable segment is expected to increase at the highest CAGR during the forecast period.
The Bisphosphonates market dominated the Global Osteoporosis Drugs Market by Drug Class in 2019. The Rank Ligand Inhibitors market is experiencing a CAGR of 4.7% during (2020 - 2026). Additionally, The Parathyroid Hormone Therapy market would exhibit highest CAGR of 4.7% during (2020 - 2026).
In the regional segment, North America is forecasted to register its dominance in the market due to the easy availability of osteoporosis drugs is expected to continue with this trend. In addition, increased osteoporosis incidence contributes to this market's growth. On the other hand, the fastest growth in Asia-Pacific over the projected period is expected to be associated with the growing concern of osteoporosis. Moreover, in emerging economies such as India, China, and Malaysia, the ever-changing life science industry is driving the market growth.
Structural Insights: https://www.kbvresearch.com/osteoporosis-drugs-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
By Route of Administration
By Drug Class
Unique Offerings from KBV Research